Who Paid My Doc
Rupali Bhave
Hematology & Oncology Winston Salem, NC
NPI 1134341993 CMS profile 395449
Medical Center Blvd, Winston Salem, NC 27157
General payments
$0
Research payments
$0
Ownership & investment interest
$0
The CMS Open Payments record contains no reported payments to Rupali Bhave of Winston Salem, NC.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
688
Drug cost
$3,806,464
Branded share of claims
46.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | Brand | 129 | $2,046,822 | |
| Imbruvica Ibrutinib | Brand | 33 | $496,609 | |
| Vonjo Pacritinib Citrate | Brand | 24 | $486,249 | |
| Sprycel Dasatinib | Brand | 18 | $225,467 | |
| Calquence Acalabrutinib Maleate | Brand | 14 | $201,548 | |
| Brukinsa Zanubrutinib | Brand | 19 | $142,459 | |
| Pegasys Peginterferon Alfa-2a | Brand | 42 | $136,160 | |
| Imatinib Mesylate | Generic | 13 | $49,753 | |
| Xarelto Rivaroxaban | Brand | 16 | $14,803 | |
| Hydroxyurea | Generic | 185 | $4,309 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 19 billing codesPaid by Medicare
$60,874
Medicare patients
130
Services billed
825
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| Diabetes | 38% | |
| Chronic kidney disease | 38% | |
| Atrial fibrillation | 32% | |
| Heart failure | 28% | |
| Ischemic heart disease | 23% | |
| Depression | 22% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Other Hematology & Oncology in North Carolina
Amit Mehta
Hematology & Oncology · Cary, NC
Michael Morse
Hematology & Oncology · Durham, NC
Shelbi Atrash
Hematology & Oncology · Charlotte, NC
Phillip Febbo
Hematology & Oncology · Durham, NC
Angela Alistar
Hematology & Oncology · Winston Salem, NC
Ravi Paluri
Hematology & Oncology · Winston Salem, NC
Related records
Hematology & Oncology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.